CXCR3型
生物
分子生物学
趋化因子
趋化性
微阵列分析技术
基因表达
受体
CXCL10型
细胞生物学
细胞因子
趋化因子受体
免疫学
基因
生物化学
作者
Deborah L. Hodge,William Bane Schill,Jiming Wang,Isaac Blanca,Della A. Reynolds,John R. Ortaldo,Howard A. Young
出处
期刊:Journal of Immunology
[American Association of Immunologists]
日期:2002-06-01
卷期号:168 (12): 6090-6098
被引量:67
标识
DOI:10.4049/jimmunol.168.12.6090
摘要
Cytokine treatment of NK cells results in alterations in multiple cellular responses that include cytotoxicity, cytokine production, proliferation, and chemotaxis. To understand the molecular mechanisms underlying these responses, microarray analysis was performed and the resulting gene expression patterns were compared between unstimulated, IL-2, IL-2 plus IL-12, and IL-2 plus IL-18-stimulated NK92 cells. RNase protection assays and RT-PCR confirmed microarray predictions for changes in mRNA expression for nine genes involved in cell cycle progression, signal transduction, transcriptional activation, and chemotaxis. Multiprobe RNase protection assay also detected changes in the expression of CCR2 mRNA, a gene that was not imprinted on the microarray. We subsequently expanded our search for other chemokine receptor genes absent from the microarray and found an IL-2- and IL-12-dependent decrease in CXCR3 receptor mRNA expression in NK92 cells. A detailed analysis of CXCR3 expression in primary NK cells revealed that an IL-2 and an IL-12 together significantly decreased the CXCR3 receptor mRNA and receptor surface expression by 6 and 24 h of treatment, respectively. This decrease in receptor expression was associated with a significant reduction in chemotaxis in the presence of IFN-gamma-inducible protein-10. The decline in CXCR3 mRNA was due to transcriptional and posttranscriptional mechanisms as the addition of actinomycin D to IL-2- and IL-12-treated NK92 slightly altered the half-life of the CXCR3 mRNA. Collectively, these data suggest that IL-2 and IL-12 directly affect NK cell migratory ability by rapid and direct down-regulation of chemokine receptor mRNA expression.
科研通智能强力驱动
Strongly Powered by AbleSci AI